4D_Molecular_Therapeutics Presents 4D-150 Data
Analysis based on 6 articles · First reported Jun 30, 2026 · Last updated Jun 30, 2026
The announcement of 4D Molecular Therapeutics' presentation on its investigational gene therapy 4D-150 at a prominent scientific meeting could positively impact investor confidence in the company. Successful presentation of clinical trial data may lead to increased interest in the biotechnology sector, particularly for companies developing treatments for retinal vascular diseases.
4D Molecular Therapeutics announced a podium presentation at the 44th Annual Scientific Meeting of the American Society of Retina Specialists, held in Canada — Montreal, Canada, from July 15-18, 2026. The presentation, delivered by Carl Awh, MD, FASRS, from United States — Tennessee, focused on the 2-year follow-up data from the PRISM Phase 2b clinical trial evaluating 4D-150, an intravitreal gene therapy for broad neovascular age-related macular degeneration (AMD). This event highlights the ongoing development of 4D-150, a lead product candidate designed to provide multi-year sustained delivery of anti-VEGF biologics for blinding retinal vascular diseases.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard